(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
Live Science on MSN
'This is a completely different level of anti-vaccine engagement than we've ever seen before,' says epidemiologist Dr. Seth Berkley
Epidemiologist Dr. Seth Berkley spoke to Live Science about the importance of vaccine equity and the obstacles undermining it ...
A study presented at the annual European Society of Medical Oncology Congress 2025 and published in the journal Annals of ...
An ex-firefighter with ties to RFK Jr. is leading the federal agency that handles public health crises and maintains the ...
This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...
The recall election is an electoral obligation for those wishing to return representative government back to the resident ...
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
US biotech Moderna (Nasdaq: MRNA) is discontinuing its once-promising vaccine for congenital cytomegalovirus (CMV) after the shot failed to prevent primary infection in healthy women during a Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback